Test for COVID-19

 

Starting from May 18th 2020, Avicena laboratory offers a comprehensive test portfolio for COVID-19, including:

 

1.        SARS-CоV-2 Real-time PCR test from nasal and oropharingeal swab

2.     Multiplex Real-time PCR test for simultaneous detection of SARS-CoV-2, Influenza A/ Influenza B and RSV from swab

3.       IMMUNOASSAY FOR QUANTITATIVE DETERMINATION of:

      - IgM+IgA+IgG  SARS-CоV-2 antibodies in blood 

      - IgG  SARS-CоV-2 antibodies in blood

      Total SARS-CоV-2 antibody concentration  

 

The combination of the two types of tests gives a complete and realistic picture of what is happening in the human body, so that immunoassays and molecular tests are complementary and complement each other. Where the molecular tests detect the presence of the virus itself or even just a sequence of RNA from the virus, by measuring the concentration of antibodies, it is possible to see if the organism has been in contact with the virus and what the body's immune response is. in the fight against this virus.

 

Real-time PCR (COVID-19) - swab sample

 

The molecular test is a golden standard in testing, because with the help of molecular techniques, the presence of the virus itself is detected, and even just a sequence of RNA on the virus itself. The test being performed in Avicena laboratory has the following features:

 

       Highly accurate and precise Real-time PCR for detection of SARS-CоV-2

       CE-IVD certified and validated for automated use 

       Uniqe test that identifies the three viral genes, with an internal control included

       In accordance with the  WHO, US CDC, Ch-CDC recommendations

 

QUANTITATIVE IMMUNOASSAY FOR  IgM + IgA and IgG SARS-CоV-2 ANTIBODIES in blood

CE-IVD certified test, with high clinical sensitivity ans specificity.

                         

Measurement of IgM, IgA, and IgG antibodies is important in:

 

      -           DIAGNOSIS IN EARLY PHASE OF THE DISEASE

The appearance of antibodies means that the organism has been in contact with the virus and the body's immune system has been activated. IgM and IgA antibodies usually occur first, about 5 to 7 days after contact with the virus, and IgG antibodies about 14 days after contact with the virus. By measuring the concentration of IgA antibodies, the clinical sensitivity of the test is further enhanced.

 

-            ASYMPTOMATIC PATIENTS

 

People who do not have or have not had any symptoms while in contact with the virus will be identified.

 

-            PATIENTS WITH CLINICAL SYMPTOMS AND NEGATIVE MOLECULAR TEST

 

There are cases when for several reasons, the molecular test may be falsely negative. In this way, the immunoassay  will help solve many dilemmas.

 

-            STAGING OF THE DISEASE

 

-            PROGNOSTIC VALUE

 

There are clinical studies that suggest that significantly increased concentrations of both types of antibodies are associated with worse disease progression and worse outcome.

 

-            FOLLOW-UP  INFECTION IN THE PAST

 

Detection of IgG antibodies in a negative molecular test suggests that we may have been in contact with the virus in the past or that we may have experienced the infection without symptoms.

 

-    SELECTION OF  PLASMA DONORS

 

The concentration of antibodies in the blood of patients who have undergone the disease is crucial to selecting patients who are suitable donors of convalescent plasma to treat COVID-19 patients

                                                                                                                    

Result interpretation*

IgM+IgA concentration

IgG concentration 

INTERPRETATION

negative

negative

Infection is excluded or the patient is in „window” period

positive

negative

Early stage of infection

positive

positive

Active phase of infection, late phase of infection or recovery

negative

positive

Late phase of infection / past infection 

 

 

*The results interpretation table is only a guide for further decision making, not a definitive diagnosis. Diagnosis of COVID-19 disease requires a combination of molecular tests, clinical examination, and findings from other clinical tests.

 

 TEST PRICE

 

MOLECULAR REAL TIME PCR ТЕСТ

 

Molecular test for SARS-CоV-2 detection                 2.600,00 MKD

 

Re-testing for COVID-19 (Molecular test for SARS-CоV-2 detection)            2.400,00 MKD

 

Multiplex Real-time PCR test for simultaneous detection of SARS-CoV-2, Influenza A/ Influenza B and RSV      3.000,00 MKD

 

IMMUNOASSAY FOR QUANTITATIVE DETERMINATION OF 

 

IgМ+ IgA and IgG SARS-CоV-2 antibodies in blood             1.800,00 MKD

IgG SARS-CоV-2 antibodies in blood                                         1.200,00 MKD

Total SARS-CоV-2 antobody concentration                         1.200,00 MKD

 

COMPLETE TEST PANEL FOR COVID-19

 

 PCR TEST + ANTIBODY CONCENTRATION (IgМ+ IgA and IgG)                3.700,00 MKD

 

       PCR TEST + TOTAL ANTIBODY CONCENTRATION                                          3.500,00 MKD

Sample collection

-Nasopharyngeal / oropharingeal swab sample for PCR SARS-CоV-2 test

-Venous blood for antibody immunoassay test (IgM +IgA , IgG  SARS-CоV-2 antobodies)

 

 

  IMPORTANT NOTICE!

 

Taking samples for COVID-19 test is being performed only in laboratory in Municipality Taftalidze (07.00 -19.00h) and Tetovo (08.00 - 14.00h).

 

 The tests for COVID-19 can be scheduled every working day and Saturday on the following phone numbers:

 

   071/278-529; 078/218-731; 071/269-623 and 072/319-850

 

   

 

Avicena Laboratory, in conditions of global COVID-19 pandemic undertakes all necessary measures on a daily basis, in order to protect the health of employees, patient health and public health,  in accordance with the guidelines of the Commission for Infectious Diseases at the Ministry of Health and WHO.